TheraCryf PLC
Company Profile
Business description
TheraCryf PLC is a biotechnology company developing new medicines for addiction and other neuropsychiatric disorders, areas of unmet medical need within central nervous system (CNS) disorders. The Group's main programme is a novel, benchmark orexin-1 receptor antagonist being developed as a potential treatment for addiction, including binge eating, alcohol, and other substance use disorders. It also has a dopamine transporter (DAT) modulator programme addressing fatigue of brain origin, including fatigue associated with multiple sclerosis, chemotherapy, and narcolepsy. The Group also has an oncology programme in glioblastoma with SFX-01. It operates a capital-light, virtual development model advancing programmes to early clinical or proof-of-concept stage before partnering.
Contact
Congleton Road
Alderley Park
Nether AlderleyCheshireSK10 4TG
GBRT: +44 1625315090
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 March 2027
Employees
9
Stocks News & Analysis
stocks
Long term outlook intact for wide moat income share
stocks
ASX rare earths play looks to expand production
stocks
Anthropic’s leaked financials reflect fast growth, but not a $2 trillion valuation
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,894.60 | 8.90 | -0.10% |
| CAC 40 | 7,823.07 | 42.00 | -0.53% |
| DAX 40 | 25,282.63 | 166.56 | -0.65% |
| Dow JONES (US) | 51,521.28 | 253.38 | 0.49% |
| FTSE 100 | 10,504.38 | 37.31 | -0.35% |
| HKSE | 24,130.50 | 150.06 | -0.62% |
| NASDAQ | 27,599.89 | 122.58 | 0.45% |
| Nikkei 225 | 70,035.71 | 648.27 | -0.92% |
| NZX 50 Index | 13,684.04 | 16.08 | -0.12% |
| S&P 500 | 7,818.93 | 44.98 | 0.58% |
| S&P/ASX 200 | 8,727.70 | 8.00 | -0.09% |
| SSE Composite Index | 3,842.19 | 11.74 | 0.31% |